The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

Helping an older adult stay consistent with breathing treatments can feel like a full-time job - especially when COPD, asthma ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

There’s a big opportunity for MAHA to include real-world experts in future studies and analyses: mental-health professionals, ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

Doctronic reports chest colds last 7-14 days, caused by viral infections or irritants, with symptoms like cough and chest ...

GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

If you suspect you have fleas or ticks in your home, follow our helpful tips to confirm whether you have a problem and when to call in an expert.

Delhi schools are shifting to digital classes for students up to Class 5 due to severe smog and hazardous air pollution ...